Siyue Jia, Zundong Yin, Hongxing Pan, Fuzhen Wang, Xiaoqiang Liu, Qing Wang, Li Zhang, Jihai Tang, Hao Yang, Jiangbo Du, Zhiguo Wang, Pengfei Jin, Zhihang Peng, Rong Tang, Guodong Kang, Xuewen Wang, Simin Li, Weixiao Wang, Jingxin Li, Hongbing Shen, Fengcai Zhu
Effectiveness of heterologous booster regimes with ad5 vectored COVID-19 vaccine in a large, diverse population during the national-scale outbreak of SARS-CoV-2 omicron predominance in China has not been reported, yet. We conducted a large-scale cohort-control study in six provinces in China, and did a retrospective survey on the COVID-19 attack risk during this outbreak. Participant aged ≥18 years in five previous trials who were primed with 1 to 3 doses of ICV received heterologous booster with either intramuscular or orally inhaled ad5 vectored COVID-19 vaccine were included in the heterologous-trial cohort...
December 2024: Emerging Microbes & Infections